# Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension

> **NCT01520285** · PHASE4 · COMPLETED · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 281 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Zanidip
- **DRUG:** Felodipine sustained-release tablet

## Key facts

- **NCT ID:** NCT01520285
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-08
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520285, "Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01520285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*